Tumor-targeting Salmonella typhimurium A1-R regresses an osteosarcoma in a patient-derived xenograft model resistant to a molecular-targeting drug

Takashi Murakami, Kentaro Igarashi, Kei Kawaguchi, Tasuku Kiyuna, Yong Zhang, Ming Zhao, Yukihiko Hiroshima, Scott D. Nelson, Sarah M. Dry, Yunfeng Li, Jane Yanagawa, Tara Russell, Noah Federman, Arun Singh, Irmina Elliott, Ryusei Matsuyama, Takashi Chishima, Kuniya Tanaka, Itaru Endo, Fritz C. EilberRobert M. Hoffman

Research output: Contribution to journalArticlepeer-review

41 Citations (Scopus)

Abstract

Osteosarcoma occurs mostly in children and young adults, who are treated with multiple agents in combination with limb-salvage surgery. However, the overall 5-year survival rate for patients with recurrent or metastatic osteosarcoma is 20- 30% which has not improved significantly over 30 years. Refractory patients would benefit from precise individualized therapy. We report here that a patient-derived osteosarcoma growing in a subcutaneous nude-mouse model was regressed by tumortargeting Salmonella typhimurium A1-R (S. typhimurium A1-R, p < 0.001 compared to untreated control). The osteosarcoma was only partially sensitive to the moleculartargeting drug sorafenib, which did not arrest its growth. S. typhimurium A1-R was significantly more effective than sorafenib (P < 0.001). S. typhimurium grew in the treated tumors and caused extensive necrosis of the tumor tissue. These data show that S. typhimurium A1-R is powerful therapy for an osteosarcoma patient-derived xenograft model.

Original languageEnglish
Pages (from-to)8035-8042
Number of pages8
JournalOncotarget
Volume8
Issue number5
DOIs
Publication statusPublished - 2017
Externally publishedYes

Keywords

  • Nude mouse
  • Osteosarcoma
  • Patient-derived xenograft
  • Salmonella typhimurium A1-R
  • Tumor-targeting

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Tumor-targeting Salmonella typhimurium A1-R regresses an osteosarcoma in a patient-derived xenograft model resistant to a molecular-targeting drug'. Together they form a unique fingerprint.

Cite this